This podcast discusses new data pertaining to glucagon-like peptide-1 receptor agonists in the treatment of diabetes and their cardioprotective properties. As the incidence of type 2 diabetes mellitus rises in the United States, understanding the results of the ELIXA trial (Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 [Lixisenatide]) will prepare you to better treat your patients.

Subscribe on iTunes | Subscribe on Google Play | View in the Educational Activity

Keywords: CardiaCast, Metabolic Syndrome, Diabetes Mellitus, Type 2, Glucagon-Like Peptide 1, Acute Coronary Syndrome, Peptides, Cardiovascular System

< Back to Listings